Dale and Betty Bumpers Vaccine Research Center search   
Vaccines for Life
Office of the Director
Research Laboratories
Clinical Studies
Collaboration and Funding
Publications News Seminars Meetings Employment
Clinical Trials
About Clinical Trials Core
* Chief's Profile
* Program Areas
* Facts
* Meet the Staff
* FAQs
* Contact Us
* Virtual CTC Clinic Tour
VRC Clinical Trials
* Understanding Vaccine Clinical Trials
* Safeguards
* Vaccine Science
* Current VRC Clinical Trials
* Archive of VRC Clinical Trials
Update on HIV Vaccine
* IAVI Report: Ongoing Trials of Preventive HIV Vaccines (PDF) [Disclaimer]
* IAVI Report: AIDS Vaccine Trials 2006: Year in Review (PDF) [Disclaimer]
* Download presentation slides by Barney Graham, M.D., Ph.D.
AIDS Information
* HIV Statistics
* HIV Transmission
Join the Human Race against HIV/AIDS Join the Human Race against HIV/AIDS

 

Clinical Trials
VRC Clinical Trials
VRC Home

Understanding Vaccine Clinical Trials

What is a Vaccine Clinical Trial?

Experimental vaccines are first tested in laboratory and animal studies for safety and immunogenicity. If the results are favorable, a vaccine must successfully complete several phases of testing in people before it can gain Food and Drug Administration (FDA) approval for licensing and marketing to the public. All the phases conduct randomized, controlled, and double-blinded studies. These studies compare the safety and effectiveness of the vaccine to an inactive placebo or a control that may be another licensed vaccine of potential benefit to the study population. *

Phases of Clinical Trials

A Phase I trial is the first setting in which an experimental vaccine is given to people. The trial, which can last up to 2 years, may enroll between 20 to 100 volunteers. A Phase I trial primarily seeks information on safety, particularly looking for any vaccine-related side effects. The trial can also provide data on the dose and administration schedule needed to achieve the optimal immune responses.

Once Phase I trials show the experimental vaccine is safe, well tolerated, and appears promising, it can advance into Phase II. These trials, which can last longer than 2 years, enroll between 100 to 300 volunteers. In these trials researchers gather more data on safety and immunogenicity.

Investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) are also developing designs for intermediate trials that can provide preliminary answers about a candidate vaccine's efficacy, and determine if the vaccine candidate should move forward into large Phase III, or efficacy, trials. A Phase IIb trial, also known as a "proof-of-concept" trial, is smaller, usually requiring 2,000 to 9,000 volunteers, and may provide clues about the immune responses that can protect against disease.

The most promising vaccine candidates move into Phase III, enrolling 10,000 or more people. A Phase III trial, which can last up to 4 years, is typically designed to ensure enough data are collected on safety and effectiveness to support a license application to FDA. *

Continue here for additional Clinical Trials Resource Information.

* Courtesy National Institute of Allergy and Infectious Diseases

 

 

*  

NIH Home

Department of Health and Human Services / National Institutes of Health / National Institute of Allergy and Infectious Disease
Vaccine Research Center / 40 Convent Drive / Bethesda, Maryland 20892
E-mail the VRC | Directions and Maps | Site Map

Office of the Director | Research Laboratories | Clinical Studies | Collaboration and Funding
NIAID Website Privacy Statement | NIAID Website Accessibility Statement

Last updated: 12.17.07 (alt)

National Institute of Allergy and Infectious Disease Home